CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-01 | Sloan Sheldon Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2024-09-03 | Burrows Scott L Chief Financial Officer | Sale | −18,531 | $28.17 | $522K | 116,422 |
| 2024-05-14 | Stelzer Laurie Director | Grant or award · Stock Option (Right to Buy) | +11,323 | 11,323 | ||
| 2024-05-14 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +11,323 | 11,323 | ||
| 2024-05-14 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +11,323 | 11,323 | ||
| 2024-05-14 | Milligan Sandra Director | Grant or award · Stock Option (Right to Buy) | +21,980 | 21,980 | ||
| 2024-05-14 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +11,323 | 11,323 | ||
| 2024-05-14 | HENDERSON MICHAEL THOMAS Director | Grant or award · Stock Option (Right to Buy) | +11,323 | 11,323 | ||
| 2024-04-25 | Fairmount Funds Management LLC Director | Option exercise | +3,639,680 | 4,018,101 | ||
| 2024-04-25 | Fairmount Funds Management LLC Director | Option exercise · Series A Preferred Stock | −90,992 | 346,045 | ||
| 2024-02-15 | Turtle Cameron Chief Executive Officer | Grant or award | +400 | $9.82 | $4K | 746,907 |
| 2024-02-01 | McKenna Mark C. Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-01 | Turtle Cameron Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +277,750 | 277,750 | ||
| 2024-02-01 | Burrows Scott L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2024-02-01 | King-Jones Heidy See Remarks | Grant or award · Stock Option (Right to Buy) | +63,000 | 63,000 | ||
| 2023-12-29 | Fairmount Funds Management LLC Director | Other disposition 10b5-1 | −3,435,480 | 0 | ||
| 2023-12-29 | Fairmount Funds Management LLC Director | Other acquisition 10b5-1 | +406,038 | 406,038 | ||
| 2023-12-29 | Fairmount Funds Management LLC Director | Other acquisition 10b5-1 | +406,038 | 406,038 | ||
| 2023-12-22 | Burrows Scott L Chief Financial Officer | Grant or award | +134,953 | 134,953 | ||
| 2023-12-07 | Fairmount Funds Management LLC Director | Grant or award · Series B Preferred Stock | +16,667 | $600.00 | $10.0M | 16,667 |
Page 9 of 11 · 213 trades